English Korean Chinese
ホーム > 市場調査レポート > 医薬品 > ワクチン > 米国における非感染症用ワクチンのパイプライン
カテゴリ
医薬品 (4964)
OTC (153)
がん (943)
ドラッグデリバリー (185)
ワクチン (181)
感染症 (353)
規制環境 (132)
後発医薬品 (135)
骨疾患 (37)
処方薬 (158)
神経疾患 (174)
精神疾患 (89)
製薬企業関連 (531)
創薬 (1524)
糖尿病 (193)
動物用医薬 (17)
肥満症 (44)
市場調査レポート

米国における非感染症用ワクチンのパイプライン

U.S. Non-Infectious Disease Vaccine Pipeline

発行 Frost & Sullivan
出版日 2008年04月 商品コード 64750
ページ情報 英文 65 Pages
価格
US$ 6,000 換算 ¥ 482,820 (税抜) Web Access (Regional License)
US$ 6,500 換算 ¥ 523,055 (税抜) Hard Copy & Web Access (Regional License)


原文目次

Abstract

The U.S. Non-Infectious Disease Vaccine Pipeline research service contains an overview of the vaccine pipeline and development information for non-infectious diseases (Oncology, Cardiovascular, Multiple Sclerosis, Addiction Disorders). The research service also provides an overview of vaccine development, major challenges, and conclusions.

Table of Contents

1 U.S. NON-INFECTIOUS DISEASES VACCINE PIPELINE

  • Introduction and Scope
    • Title
    • Disclaimer
    • Certification
    • Table of Contents
    • Introduction and Scope
  • Vaccine Development
    • Clinical Development
    • Challenges
    • Market Trends
  • Cancer Vaccine Pipeline by Disease
    • Cancer Vaccine Pipeline by Disease
    • Acute Myelogenous Leukemia
    • Breast Cancer
    • Chronic Myleoid Leukemia
    • Colorectal Cancer
    • Esophageal Cancer
    • Glioblastoma Multiforme
    • Head and Neck Cancer
    • Liver Cancer
    • Lung Cancer
    • Melanoma
    • Non-Hodgkin Lymphoma
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Renal Cell Carcinoma
  • Addiction Vaccine Pipeline by Disease
    • Addiction Vaccine Pipeline by Disease
    • Cocaine Abuse
    • Nicotine Abuse
  • Cardiovascular Disease Vaccine Pipeline by Disease
    • Cardiovascular Disease Vaccine Pipeline by Disease
    • Hyperlipidemia
    • Hypertension
  • Multiple Sclerosis Vaccine Pipeline
    • Multiple Sclerosis Vaccine Pipeline
    • Multiple Sclerosis
  • Conclusion
    • Conclusion Introduction
    • Conclusion
  • Appendix
    • About Frost & Sullivan
Back to Top